Latest / Views and News with Clarence Ford / SASOP concerned about the shortage of essential medications for the treatment of mental disorders in the public health sector
Transcript
- 0:00Speaker 1: Welcome back, and yeah, there's been quite a couple of
- 0:02Speaker 1: messages in via the WhatsApp line on 0725671567, people wanting
- 0:09Speaker 1: to understand more about the shortage of very chronic stockouts
- 0:16Speaker 1: of drugs in the public sector of South Africa. Today
- 0:19Speaker 1: we're going to talk about psychiatric drugs and specifically psychotropic
- 0:23Speaker 1: medications that are in short supply. The South African Society
- 0:27Speaker 1: of Psychiatrists SASOP recently issued urgent calls to Health Minister
- 0:32Speaker 1: Eran Matsualedi to investigate widespread supply disruptions impacting, and we're
- 0:38Speaker 1: talking schizophrenia, we're talking bipolar disorder, we're talking major depressive
- 0:43Speaker 1: disorders across major provinces, Khauteng, KwaZulu-Natal, the Western Cape, and
- 0:47Speaker 1: the Eastern Cape. My privilege to talk to Dr. Nokatula Mdaka,
- 0:55Speaker 1: an extensive background in public sector psychiatry, severe mental illness
- 1:00Speaker 1: and addiction psychiatry via Stellenbosch University and the South African
- 1:03Speaker 1: Addiction Medicine Society will give us some key insights into
- 1:07Speaker 1: the issues. Welcome, Dr. Mdaka. It's always great to be
- 1:10Speaker 1: able to chat with you.
- 1:12Speaker 2: Hi, how are you? And good morning to all your
- 1:14Speaker 2: listeners as well.
- 1:16Speaker 1: Yeah, so SASOP has raised the alarm over widespread shortages
- 1:21Speaker 1: and we're looking at pretty serious kind of medication that
- 1:26Speaker 1: appears to be out of stock What are your colleagues
- 1:30Speaker 1: in the front lines of, well, in public facilities actually experiencing?
- 1:35Speaker 1: Let us know.
- 1:37Speaker 2: Yeah, so, you know, at SASOP we received several complaints
- 1:42Speaker 2: or rather reports from our members from all over South Africa.
- 1:47Speaker 2: All the provinces actually report that, you know, medication for
- 1:52Speaker 2: most of the patients common and severe mental illnesses, like
- 1:56Speaker 2: your major depressive disorder, your schizophrenia, your bipolar disorder, that
- 2:01Speaker 2: the medication has been out of stock. And examples of
- 2:05Speaker 2: the medication that is out of stock, you know, includes
- 2:09Speaker 2: your medication called olanzapine, which is medication that we commonly
- 2:14Speaker 2: use to treat schizophrenia and bipolar disorder. And there hasn't
- 2:20Speaker 2: been clear explanations as to why we are actually experiencing
- 2:25Speaker 2: these widespread shortages. And what we are finding that is
- 2:30Speaker 2: that it's really impacting negatively, not only on the patients,
- 2:35Speaker 2: but also on the health system at large and the
- 2:39Speaker 2: communities at large. And I mean, as you can imagine,
- 2:43Speaker 2: if a patient with a severe mental illness doesn't get
- 2:46Speaker 2: their medication for more than a month, they will relapse.
- 2:50Speaker 2: And that relapse is going to impact negatively on the
- 2:54Speaker 2: health system as well because you end up having to
- 2:57Speaker 2: actually admit that patient. And, you know, nationally, we've got
- 3:02Speaker 2: big issues as well in terms of shortages of acute
- 3:05Speaker 2: psychiatric beds.
- 3:07Speaker 1: And that relapse would maybe also include psychotic episodes, which...
- 3:15Speaker 1: I would imagine it's very traumatic, especially for families.
- 3:19Speaker 2: Yes, definitely. So obviously, depending on the disorder that the
- 3:24Speaker 2: patient is suffering from. But if you do have someone
- 3:28Speaker 2: with schizophrenia and even someone with bipolar disorder, they can
- 3:33Speaker 2: definitely have psychotic episodes. And, you know, a lot of
- 3:36Speaker 2: the times when patients are psychotic, they do end up
- 3:40Speaker 2: being aggressive. And that's also where then the risk to
- 3:44Speaker 2: the individual, their families, and the community at large then
- 3:50Speaker 2: comes into play. But remember, a lot of patients with
- 3:53Speaker 2: psychiatric disorders are also employed. So there are other economic
- 3:59Speaker 2: risks as well to the individual and their families. And
- 4:04Speaker 2: what we sometimes find is that the more a patient
- 4:07Speaker 2: has relapses, the more difficult it becomes to treat them.
- 4:11Speaker 2: You know, to get them out of that relapse. Sometimes
- 4:15Speaker 2: they end up not responding to medication that they previously
- 4:19Speaker 2: responded to. Sure.
- 4:21Speaker 1: Okay, so we know that the private sector is stocked
- 4:24Speaker 1: up and not the public sector. We know, too, that,
- 4:28Speaker 1: you know, especially raw material shortages hit supply intermittently. We
- 4:35Speaker 1: know that we've got localized tender management issues. We've got
- 4:38Speaker 1: budget constraints. We know about provincial supply chain failures. But
- 4:43Speaker 1: because it does not exist in the private sector, can
- 4:46Speaker 1: we conclude this is not a global problem?
- 4:51Speaker 2: I think we can conclude that because there are some
- 4:54Speaker 2: psychotropic medications that are also not available in the private sector.
- 5:00Speaker 2: So we can't really conclude that it's only a public
- 5:04Speaker 2: sector problem. There are a few. Although in the public
- 5:08Speaker 2: sector we've got more medication that is not available and
- 5:12Speaker 2: we don't have clear reasons or explanations why. as to
- 5:16Speaker 2: why those medications are not available. And that's why, you know,
- 5:20Speaker 2: we were thinking that it's probably the tender processes that
- 5:24Speaker 2: have gone wrong and also issues with pricing, where we
- 5:31Speaker 2: sometimes find that maybe the government has proposed the pricing
- 5:35Speaker 2: at a much lower price that the pharmaceutical companies are
- 5:38Speaker 2: not willing to take. But actually....
- 5:43Speaker 1: I think we're also very aware of what the pharmaceutical
- 5:46Speaker 1: companies are sometimes capable of. But let's look at Dr.
- 5:51Speaker 1: Aaron Matsualedi. You've flagged this issue to him. What was
- 5:55Speaker 1: his response to you?
- 5:59Speaker 2: There has been a media statement that has been taken
- 6:01Speaker 2: out by the National Department of Health responding to this
- 6:07Speaker 2: call of the shortages of medication. So the minister has
- 6:13Speaker 2: not ignored this. The National Department of Health has also
- 6:18Speaker 2: taken out an official media statement highlighting these shortages. And
- 6:23Speaker 2: I must say, it's also not just psychotropic medications. I
- 6:27Speaker 2: know that today we're focusing on psychotropic medications, but there
- 6:30Speaker 2: are other medications, for example, medication to treat diabetes and
- 6:35Speaker 2: hypertension that is also out of stock. So it's somewhat
- 6:39Speaker 2: a global issue when it comes to medication for chronic illnesses.
- 6:44Speaker 1: Global, you say, it's not unique to South Africa.
- 6:48Speaker 2: No. well, if I'm talking about nationally, it's globally across
- 6:53Speaker 2: most of the chronic illnesses.
- 6:55Speaker 1: So it's a South African problem. Yeah, we've heard about this.
- 6:59Speaker 1: We've heard it manifest in oncology as well. Now, we
- 7:03Speaker 1: know that you would have line of sight of psychiatric drugs.
- 7:06Speaker 1: So now we've got a sense of it. Are we
- 7:09Speaker 1: going to solve this particular problem or are we going
- 7:11Speaker 1: to have another crisis?
- 7:16Speaker 2: That's a difficult one. I mean, as As a clinician,
- 7:21Speaker 2: as a public health advocate, I would want us to
- 7:26Speaker 2: solve this problem. I do think that it's a problem
- 7:28Speaker 2: that can be solved. It just needs all the key
- 7:32Speaker 2: stakeholders to play their role. We can definitely solve this problem.
- 7:38Speaker 1: Is it playing a role that is not well defined
- 7:41Speaker 1: or is it about key stakeholders doing their jobs?
- 7:45Speaker 2: I think it's a combination of everything. I think it's
- 7:48Speaker 2: a combination of everything. And when we refer to the
- 7:51Speaker 2: key stakeholders, we're not just referring to the government as well.
- 7:54Speaker 2: We're also referring to the pharmaceutical companies. We're also referring
- 7:59Speaker 2: to us as clinicians.
- 8:01Speaker 1: I got you. I'm just really worried, and I think
- 8:04Speaker 1: worried especially for people that are suffering a psychiatric condition
- 8:08Speaker 1: at this particular stage. And we'll keep on touching base. Dr.
- 8:13Speaker 1: Nokatula Mdaka, board member of the South African Association As psychiatrists,
- 8:20Speaker 1: how does this impact government institutions, specifically homes for people
- 8:22Speaker 1: with mental illness?